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LABORATORY STUDY
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ABSTRACT
Oxidative stress and inflammation are highly intertwined pathophysiological processes. We ana-
lyzed the markers of these processes and high-sensitive troponin I (hsTnI) for mortality prediction
in patients on haemodialysis. This study enrolled a total of 62 patients on regular haemodialysis.
The patients were monitored for two years, and the observed outcomes were all-cause and car-
diovascular mortality. Blood samples were taken before one dialysis session for analysis of the
baseline concentrations of prooxidant–antioxidant balance (PAB), total antioxidant status (TAS),
total oxidative status (TOS), hsTnI, hsCRP and resistin. The overall all-cause mortality was 37.1%
and CVD mortality 16.1%. By univariate and multivariate logistic regression, our findings suggest
that good predictors of all-cause mortality include hsCRP and PAB (p< .05) and of CVD mortality
hsCRP (p< .05) and hsTnI (p< .001). To evaluate the relationship between the combined param-
eter measurements and all-cause/CVD mortality risk, patients were divided into three groups
according to their PAB, hsCRP and hsTnI concentrations. The cutoffs for hsCRP and hsTnI and the
median for PAB were used. Kaplan–Meier survival curves pointed out that the highest mortality
risk of all-cause mortality was in the group with hsCRP levels above the cutoff and PAB levels
above the median (p< .001). The highest risk of CVD mortality was found in the group with
hsCRP and hsTnI levels above the cutoff levels (p¼ .001). Our data suggest that hsCRP and PAB
are very good predictors of all-cause mortality. For CVD complications and mortality prediction in
HD patients, the most sensitive parameters appear to be hsTnI and hsCRP.
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Introduction
Despite novel therapy management and intervention
strategies, the poor survival rate of patients with end-
stage renal disease (ESRD) on haemodialysis (HD)
remains an issue of great concern worldwide. Since the
major causes of death are cardiovascular diseases (CVD),
different CVD risk biomarkers have been studied and
many of them have been shown to be powerful predic-
tors of mortality [1,2].
Oxidative stress can be considered as an imbalance
in the reactive oxygen species (ROS) production/deg-
radation ratio. Renal dysfunction is frequently associ-
ated with oxidative stress, since the levels of different
markers like malondialdehyde and F2-isoprostanes are
increased in patients with ESRD [3,4]. Additionally,
in ESRD, a reduction in the plasma total antioxidant
capacity (TAC) levels has been observed, probably due
to malnutrition, a regular complication of this disease
[5]. Oxidative stress in HD patients is usually assessed
by measuring prooxidant levels, such as concentrations
of malondialdehyde or hydroperoxides, or antioxidants
like superoxide dismutase or myeloperoxidase activities.
Prooxidant–antioxidant balance (PAB) is the only oxida-
tive stress biomarker which measures prooxidants and
antioxidants simultaneously in one sample, assessing
their balance.
Cardiac troponin T (cTnT) and troponin I (cTnI) reflect
ischemic cardiac damage, but in patients with severe
renal disease, their levels are elevated without any evi-
dence of acute coronary syndrome (ACS).
Asymptomatic elevation of cardiac troponins in HD
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patients is possibly linked with oxidative stress and
inflammation [6,7]. The elevation of cTnT and cTnI levels
in HD patients corresponds with a 2- to 5-fold increase
in mortality. The prevalence of cTnT increment in those
patients is higher than that of cTnI [8,9]. Highly sensitive
assays of cardiac troponins can detect even minor myo-
cardial injury. Highly sensitive troponin T (hsTnT) has
been studied more extensively as a mortality predictor
in the HD population compared to troponin I (hsTnI).
Numerous studies have reported an association
between markers of inflammation like CRP, IL-6, TNF-a
and fibrinogen and chronic kidney disease (CKD) [10].
Moreover, it has been shown that elevated CRP, IL-6
and fibrinogen are independent predictors of cardiovas-
cular outcomes in CKD patients [11].
It is known that oxidative stress subsequently causes
inflammation which is the key factor of many human
diseases including coronary diseases [12]. Oxidative
stress and inflammation are highly intertwined proc-
esses in CKD, main causes of chronic kidney disease
progression development and associated complications
among which the central role has CVD [13].
Resistin is an adipocytokine and is known to be asso-
ciated with inflammatory, metabolic and vascular
abnormalities. The serum concentration of resistin is
elevated in patients with end-stage renal disease, and
there is a strong correlation between resistin and hsCRP
concentrations and resistin and residual renal function
in CKD patients [14,15]. High levels of resistin correlate
with mortality in patients with coronary disease or
acute myocardial infarction and the levels of this marker
were predictors of atrial fibrillation in the Framingham
Heart Study population. In addition, some authors have
confirmed the significance of the serum resistin for mor-
tality prediction in CKD patients [16,17].
The aim of this study is to evaluate the mortality risk
predictive value of oxidative stress and inflammation
biomarkers in haemodialysis patients. In the study, we
have also included hsTnI, a marker of ischemic cardiac
damage (Table 1).
Methods
Study design
This was a single-centre prospective study which
enrolled patients on regular haemodialysis treatment at
the Hemodialysis Centre of the Clinical Centre of
Montenegro in Podgorica, Montenegro. The Ethics
Committee of the Clinical Centre of Montenegro
approved the study and all the patients gave written
informed consent. Laboratory data were collected
before one HD session at the study start, and then
clinical status of the patients was monitored for two
years (September 2013–September 2015). Our primary
observed outcomes were all-cause mortality and mor-
tality due to cardiovascular disease (CVD mortality).
Patients and clinical data
The patients enrolled in this study were diagnosed with
ESRD according to K/DOQI guidelines [18]. All the
patients were on maintenance haemodialysis three
times per week, with an average duration of single ses-
sion being 4 h, using high-flux dialyzers with polysul-
fone membranes. The exclusion criteria were as follows:
undergoing dialysis for less than 3months, malignancy,
acquired immunodeficiency, metabolic diseases, hepatic
cirrhosis, patients on antiviral therapy and those taking
antioxidants and vitamins, except vitamin D and folic
acid, prior to dialysis. The prevalence of CVD in studied
population was 39% with coronary heart disease and
peripheral vascular disease being the most prevalent.
Patients were not hospitalized in the previous two
weeks and none had the symptoms of ACS. From all the
patients, we obtained the relevant data (age, gender,
weight, height, primary renal disease, duration of dialy-
sis from the first session until the observed one, smok-
ing habit, past medical history and current
medications). The adequacy of the dialysis was deter-
mined by calculating the Kt/V and the urea reduction
rate (URR). A Kt/V value of >1.2 and URR >65% were
indicators of an adequate dialysis dose. Pre- and post-
dialysis blood pressures (BPs) were measured for all the
patients. Pre-dialysis BP was measured at the beginning
of HD after 15min at rest. Post-dialysis BP was meas-
ured at the end of HD, 15min after disconnecting from
the dialysis circuit. Body mass index (BMI) was calcu-
lated using the standard formula: body weight in kilo-
grams/(body height in meters)2. The body weight in
this formula was oedema-free mass, i.e. post-dialysis dry
weight, according to recommendations [19].
Blood samples and laboratory data
Blood samples were withdrawn before dialysis for meas-
urement of the baseline concentration of the following
biochemical parameters: creatinine, urea, uric acid and
their associated markers: cholesterol, triglycerides, HDL
cholesterol, LDL cholesterol, apoAI, apoB, hsCRP, resis-
tin, prooxidant–antioxidant balance (PAB), total antioxi-
dant status (TAS), total oxidative status (TOS) and hsTnI.
Creatinine, urea, uric acid, cholesterol, triglycerides, HDL
cholesterol and LDL cholesterol were measured on a
Cobas c6000 (Roche Diagnostic, GmbH, Mannheim,
Germany) by routine spectrophotometric methods;
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hsTnI on an Architect i2000 (Abbott Laboratories,
Diagnostic Division, Abbott Park, IL); and apoA, apoB
and hsCRP on a BNII nephelometer (Siemens Healthcare
GmBH, Erlangen, Germany) by immunoassays. The
prooxidant–antioxidant balance (PAB) was measured
according to a previously published method by
Almadari et al. [20] modificated in biochemical labora-
tory at Faculty of Pharmacy in Belgrade. Method prin-
ciple is based on 3,3',5,5'-tetramethylbenzidine and its
cation, which were used as redox indicators. They par-
ticipate in two simultaneous reactions. Standard solu-
tions were prepared by mixing varying proportions of
0–100% of 250lmol/L hydrogen peroxide with
10mmol/L uric acid. The intra-assay and inter-assay
coefficients of variation were 6.6% and 7.2%, respect-
ively. PAB values are expressed in arbitrary HK units,
which correspond to the percentage of hydrogen per-
oxide in the standard solution. TOS was measured by
the method of Erel et al. [21]. Serum TAS levels
were determined by a novel automated method of
Miller et al. using commercial kit (Randox Laboratories
Limited, Crumlin County Antrim, UK) [22]. Resistin was
estimated by Sandwich ELISA kit (R&D Systems, Inc.,
Minneapolis, MN) suitable for measuring natural and
recombinant human resistin in most cell culture super-
nate, serum and plasma. The majority of the variables
were determined on the day the blood samples were
taken. The rest were stored at 80 C.
Statistical analysis
Continuous variables were expressed as mean± SD or
median with interquartile range, and categorical varia-
bles were expressed as a percentage. Comparisons
between groups were analyzed using an independent t-
test or a Mann–Whitney U-test for continuous variables
and the Pearson X2test for categorical variables. Binary
univariate logistic regression was used to identify the
predictors of mortality in HD patients. Survivors in both
groups were used as the reference groups and were
coded 0. Non-survivors (all-cause) and non-survivors
(CVD) were coded 1. For each hazard ratio (HR),
we estimated two-tailed probability values and the 95%
confidence interval (95% CI). To seek possible independ-
ent predictors of mortality in HD patients, we per-
formed multiple logistic regression analysis where all
significant predictors by univariate analysis adjusted for
other variables with p< .1 in univariate analysis.
Adjustment was performed to correct the possible inter-
action of investigated parameters. The Kaplan–Meier
survival curve at 24months was used to evaluate the
difference between combined variables with significant
ability for mortality prediction proven by logistic regres-
sion. Groups were compared using a log-rank test. All
the statistical tests were two-sided, and differences
were considered statistically significant where the
p-value< .05.
Results
A total of 62 patients (30 males and 32 females) with a
mean age of 57.8 ± 10.2 years are enrolled in this study.
The aetiologies of CKD are as follows: hypertension
in 20 patients (32.3%), polycystic kidney disease in
12 patients (19.4%), chronic glomerulonephritis in
7 patients (11.3%), diabetes mellitus in 5 patients
(8.1%), chronic pyelonephritis in 3 patients (4.8%), kid-
ney stones in 3 patients (4.8%), Balkan endemic nephr-
opathy in 2 patients (3.2%), other conditions in
7 patients (11.3%) and unknown cause in 3 patients
(4.8%). After 2 years, the overall all-cause mortality
was 37.1% (23 patients) and CVD mortality 16.1%
(10 patients). In Table 2, the basic demographic charac-
teristic and the routinely assessed baseline variables
according to patient’s survival status are presented.
There were no significant differences between the
survival and both non-survival groups for age, sex, BMI
and smoking habit. Regarding the adequacy of a single
Table 1. Biomarkers studied in this paper.
Biomarker (abbreviation) Biomarker (full name) Biochemical significance Summary of our findings
hsCRP High-sensitive CRP Inflammatory marker Great predictor of mortality, all-cause and CVD
PAB Prooxidant–antioxidant balance Marker of both oxidative and anti-
oxidative processes
Great predictor of all-cause mortality, in com-
bination with CRP even better prediction
possibility
TAS Total antioxidative status Measure of antioxidative protection Significantly higher in survival group, no signifi-
cance in mortality prediction
TOS Total oxidative status Marker of oxidative stress No significance between survivors and non-sur-
vivors, no significance in mortality prediction
hsTnI High-sensitive troponin I Reflects ischemic damage of
cardiomyocytes
Predictor of CVD mortality, the best prediction
possibility when used with CRP
Resistin Resistin Inflammatory cytokine, link
between inflammation with
metabolic and vascular
pathways
No significance between survivors and non-sur-
vivors, no significance in mortality prediction
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dialysis session, Kt/V and URR values were the highest
among survivors, but there were no significant differen-
ces between the groups. Cholesterol, HDL cholesterol
and LDL cholesterol were significantly higher among
survivors compared to all-cause non-survivors.
Univariate logistic regression shows a significant rela-
tionship between total cholesterol and LDL cholesterol
in all-cause mortality (Table 3), but the significance dis-
appeared in the multivariate model (Table 4). No signifi-
cant difference was found between the groups for BMI.
The creatinine level measured before the HD session
was higher in the survival group compared to the
non-survival ones. Table 5 describes the biochemical
markers of inflammation, oxidative stress and hsTnI
according to their survival status.
After a comparison of the HD survival group with the
all-cause and CVD mortality, we concluded that there
was a significant difference between survivors and all-
cause non-survivors, and survivors and CVD non-survi-
vors for the following parameters: hsCRP (p< .001,
p¼ .001, respectively), hsTnI (p< .001, p¼ .039, respect-
ively) and PAB (p< .001, p¼ .013, respectively). We also
found significant difference for TAS but only between
the survival and the all-cause mortality group (p¼ .027).
hsCRP, hsTnI and PAB were all higher in the non-sur-
vival group. TAS levels were lower in the group of all-
cause non-survivors compared to the survivors. In our
study, resistin shows no significant differences between
groups.
We used binary logistic regression to determine
which of the investigated parameters had potential to
predict all-cause and CVD mortality in HD patients.
Unadjusted analysis indicated that age, TC, LDL-C,
hsCRP, hsTnI, TAS and PAB concentrations were predic-
tors of mortality in all-cause mortality group, while
HDL-C, hsCRP, hsTnI and PAB concentrations were sig-
nificant predictors in CVD mortality group (Table 3).
Table 3. Predictors of all-cause and CVD mortality: univariate
logistic regression analysis (enter method).
Mortality
All-cause CVD
Variables HR (95% CI)a p HR (95% CI)a p
Age, years 1.064
(1.012–1.118)
<.05b 1.051
(0.974–1.135)
.198
Smoking 1.01
(0.424–2.408)
.982 2.013
(0.418–9.691)
.383
BMI, kg/m2 1.017
(0.907–1.141)
.768 1.072
(0.893–1.286)
.457
TC, mmol/L 0.54
(0.319–0.917)
<.05b 0.541
(0.239–1.221)
.139
TG, mmol/L 1.158
(0.632–2.12)
.636 0.817
(0.239–2.285)
.700
LDL-C, mmol/L 0.372
(0.176–0.783)
<.05b 0.440
(0.140–1.389)
.162
HDL-C, mmol/L 0.341
(0.080–1.456)
.146 0.142
(0.015–1.327)
.087b
hsCRP, mg/L 1.021
(1.010–1.033)
<.001b 1.023
(1.005–1.048)
.054b
Resistin, mg/L 0.691
(1.93–2.481)
.571 1.283
(0.226–7.280)
.779
hsTnI, ng/L 1.007
(1.004–1.011)
<.001b 1.010
(1.004–1.016)
<.001b
TAS, mmol/L 0.061
(0.006–0.653)
<.05b 0.096
(0.003–1.746)
.171
TOS, lmol/L 1.006
(0.985–1.026)
.594 1.008
(0.981–1.036)
.551
PAB, HK units 1.035
(1.021–1.049)
<.05b 1.003
(1.012–1.055)
<.05b
aHR: hazard ratios; 95% CI: 95% confidence interval.
bVariables with p< .10 were entered in multivariate logistic regression
analysis.
Table 2. Characteristics of patients according to their survival status.
Survivors n¼ 39
Non-survivors
all-cause n¼ 23
p-Value survivors,
non-survivors all-cause
Non-survivors
CVD n¼ 10
p-Value survivors,
non-survivors CVD
Age, years 57.5 (50.25–63.0) 60.0 (55.0–68.5) .077 56.0 (55.0–67.5) .709
Sex 53.8% males(21) 39.1% males (9) .393 60%males (6) 1
BMI, kg/m2 23.09 ± 3.27 23.48 ± 3.58 .631 23.86 ± 3.16 .363
Smokers 35.9%(14) 34.8% (8) .862 20%(2) .463
HD duration, days 1148 (471–2340.25) 1777.5 (425–3148) .264 1656 (372.5–2401) .778
Systolic before HD,
mmHg
143.9 ± 21.8 139.5 ± 23.2 .465 148.3 ± 24.7 .385
Systolic after HD, mmHg 130.4 ± 20.4 127.7 ± 25.8 .661 135.6 ± 30.5 .511
Kt/V 1.16 (1.05–1.25) 1.10 (0.97–1.20) .083 1.08 (1.01–1.14) .281
URR 64.1 (58.8–68.4) 59.7 (53.2–67.1) .124 57.8 (48.5–65.1) .108
Urea before HD mmol/L 29.5 ± 5.9 30.9 ± 7.9 .433 34.8 ± 7.9 .012
Creatinine before HD,
lmol/L
1038.8 ± 197.8 910.3 ± 198.4 .016 964.4 ± 208.8 .658
Uric before HD, lmol/L 412.1 (361.0–482.2) 411.5 (362.5–502.4) .503 406.6 (369.3–479.3) .826
Cholesterol, mmol/L 4.36 (3.67–4.72) 3.72 (3.06–4.36) .041 4.03 (3.09–4.11) .138
Triglycerides, mmol/L 1.43 ± 0.61 1.53 ± 0.68 .59 1.38 ± 0.42 .649
HDL cholesterol, mmol/L 0.86 (0.74–1.07) 0.73 (0.62–0.89) .025 0.73 (0.61–0.81) .065
LDL cholesterol, mmol/L 2.55 (2.12–3.02) 2.03 (1.92–2.65) .008 2.03 (1.95–2.66) .153
ApoAI, g/L 1.38 ± 0.23 1.27 ± 0.24 .089 1.24 ± 0.20 .135
ApoB, g/L 0.79 ± 0.17 0.80 ± 0.18 .742 0.83 ± 0.18 .443
Data are presented as Mean ± SD, Median (25–75 percentile) or percentage (count) and were compared by the Student’s t test or Mann-Whitney U non-
parametric test, whereas categorical variables are presented as relative frequencies and were compared by the Chi-square test.
CVD: cardiovascular disease; BMI: body mass index; HD: hemodialysis; URR: urea reduction rate.
Bold values indicates statistically significant p-value < .05.
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Thereafter, we constructed new logistic regression
models to further test the potential independent pre-
dictive power of significant predictors by univariant
analysis (Table 4). After adjustments, hsCRP and PAB
concentrations remained significant independent pre-
dictors of mortality in the all-cause mortality group. In
CVD mortality group, hsCRP and hsTnI continued to be
significant predictors.
In order to evaluate the relationship between com-
bined parameter concentrations and all-cause and CVD
mortality risk, we divided the patients into three groups
according to their PAB, hsCRP and hsTnI concentrations
(parameters that showed significant predictive power
by multivariate analysis). We have used cutoffs for
hsCRP of 5mg/L for all-cause and 3mg/L for CVD mor-
tality. The American Heart Association and the Centres
for Disease Control and Prevention (AHA/CDC) have
issued guideline for the utility of hsCRP in the primary
prevention setting and in patients with ACS. The guide-
line recommended that a hsCRP concentration higher
than 3mg/L should be considered as a high risk for
CVD development [23]. Also, hsCRP concentrations
higher than 5mg/L referred some inflammation process
in organism, so we used this cutoff for all-cause mortal-
ity. For PAB, the median of values from our study was
used as cutoff value for Kaplan–Meier survival curve
constructions. As cutoff value for hsTnI, we used
26.2 ng/L that is the 99th percentile value, recom-
mended by manufacturer (Architect STAT High
Sensitive Troponin-I, Abbott Laboratories, Diagnostic
Division, Abbott Park, IL).
In the all-cause mortality group were 23 patients
with CRP values below 5mg/L and PAB lower than the
median, 22 patients with CRP or PAB higher than the
cutoffs/median and 17 patients with PAB and CRP
above the median/cutoffs. According to the
Kaplan–Meier survival curves, the highest mortality risk
for all-cause mortality was in the group with hsCRP lev-
els above the cutoff and PAB levels above the median
(p< .001). There was one deceased patient in the first
group, nine in the second and 13 patients in the third
group, respectively (Figure 1).
For CVD mortality assessment, we had three groups
with 19, 27 and 16 patients. None of the patients from
the first group with hsCRP and hsTnI concentrations
lower than the cutoffs had cardiovascular complication
over a 2-year period. However, four patients in the
group with elevated hsCRP or hsTnI and six patients in
the group with both markers above the cutoff died
from a cardiovascular cause. The highest risk for cardio-
vascular deaths was related to hsCRP and hsTnI levels
above the cutoffs (p¼ .001) (Figure 2).
Discussion
The main goal of our study was to assess the potential
significance of serum inflammatory markers, markers of
oxidative stress and antioxidant protection as well as
hsTnI in the mortality prediction of ESRD patients on
haemodialysis.
There were no significant differences between
groups for age, sex, smoking habit and systolic blood
pressure. Although the lowest value of the calculated
BMI levels was in the group of survival patients
(23.09 ± 3.27), there were no significant differences
Table 4. Predictors of all-cause and CVD mortality: multivari-
ate logistic analysis.
Mortality
All-cause CVD
Variables HR (95% CI)a pb HR (95% CI) pc
Age, years 1.014
(0.944–1.088)
.707 –
TC, mmol/L 2.046
(0.517–8.090)
.307 –
LDL-C, mmol/L 0.168
(0.019–1.496)
.110 –
HDL-C, mmol/L – – 0.029 .166
hsCRP, mg/L 1.085
(1.015–1.160)
<.05 1.076
(1.019–1.136)
<.05
hsTnI, ng/L 1.003
(0.997–1.009)
.340 1.013
(1.005–1.021)
<.001
TAS, mmol/L 0.027 .091 – –
PAB, HK units 1.027
(1.001–1.054)
<.05 1.010
(0.976–1.045)
.566
aHR: hazard ratios; 95% CI: 95% confidence interval.
b,c Values are adjusted for other variables with p< .10 in univariate logis-
tic regression analysis.
Bold values indicates statistically significant p-value < .05.
Table 5. Characteristics of patients according to their survival status.
Survivors n¼ 39
Non-survivors
all-cause n¼ 23
p-Value survivors,
non-survivors all-cause
Non-survivors
CVD n¼ 10
p-Value survivors,
non-survivors CVD
hsCRP, mg/L 2.59 (1.03–4.47) 12.20 (2.39–17.8) <.001 13.7 (8.79–17.1) .001
Resistin, mg/L 0.71 (0.52–1.03) 0.61 (0.50–0.75) .386 0.72 (0.59–0.95) .275
hsTnI, ng/L 12 (7–26) 38 (21.0–69.0) <.001 40 (17.5–229.75) .039
TAS, mmol/L 2.25 (2.11–2.32) 2.11 (2.04–2.20) .027 2.12 (1.99–2.25) .289
TOS, lmol/L 44.51 ± 24.43 48.87 ± 21.98 .545 50.52 ± 24.83 .52
PAB, HK units 14.86 (7.63–25.71) 39.66 (28.99–58.81) <.001 42.13 (28.39–58.81) .013
Data are presented as Mean ± SD, Median (25–75 percentile) and were compared by the Student’s t test or Mann-Whitney U nonparametric test.
CVD: cardiovascular disease; TAS: total antioxidant status; TOS: total oxidant status; PAB: prooxidant-antioxidant balance.
Bold values indicates statistically significant p-value < .05.
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between the groups. The adequacy of a single dialysis
session and the duration of HD treatments in days from
the first session to the observed one were also not sig-
nificant. HDL cholesterol in our study was higher in the
survival compared to the all-cause non-survival group.
Total cholesterol and LDL cholesterol were also signifi-
cantly higher among survivors compared to all-cause
non-survivors. These two findings speak in favour of
‘reverse epidemiology’ in CKD patients. Some studies
have suggested that not only total
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Figure 1. Kaplan–Meier survival curves by hsCRP and PAB groups (all-cause mortality).
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Figure 2. Kaplan–Meier survival curves by hsCRP and hsTnI groups (CVD mortality).
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hypercholesterolemia but also LDL hypercholesterol-
emia tends to show a paradoxical association with bet-
ter survival [24]. On the other hand, patients with CKD
are at very high risk of developing CVD, and the recom-
mended LDL cholesterol plasma value for them is below
1.8mmol/L [25]. In our study, only 13.3% of patients
had target LDL cholesterol values. Total cholesterol and
LDL cholesterol showed a significant relationship with
all-cause mortality using univariate logistic regression
(Table 3), but that significance disappeared in the multi-
variate model (Table 4).
Resistin was included in the study because of its
strong relationship with inflammation, vascular path-
ology and mortality prediction in patients with coronary
heart disease, but our data could not prove the signifi-
cance of resistin in clinical outcome of HD patients.
We investigated the mortality prediction value of
three oxidative stress biomarkers and concluded that
TAS was significantly lower in the all-cause mortality
group compared to survivals but without significance in
the CVD mortality group. One cause of decreased anti-
oxidant capacity in HD patients is the loss of antioxi-
dants via the dialysis process [26]. On the other hand,
TOS was higher in both non-survival groups, but with-
out significant differences between the groups. The PAB
assay can measure simultaneously the prooxidant bur-
den and the antioxidant capacity in one assay, giving
thereby a redox index [27]. In our study, PAB was dem-
onstrated to be the best marker of increased oxidative
stress and the high impact of oxidative stress on mortal-
ity in maintenance haemodialysis patients. Univariate
logistic regression for PAB in all-cause and CVD mortal-
ity groups showed the significance for both (p< .05)
but after multivariate logistic regression analysis that
significance remained only for all-cause mortality
(p< .05). In summary, the role of oxidative stress in
renal dysfunction is often underappreciated in clinical
practice, but emerging evidence continues to highlight
its strong correlation with cardiovascular morbidity and
mortality [28]. Kaplan–Meier survival analysis for the
combination of the hsCRP cutoff value (5mg/L) and the
median of the PAB value showed that the highest risk
of all-cause mortality was in the group of patients with
hsCRP values above the cutoff and PAB values above
the median. There were 17 patients in that group and
13 of them diseased. Many oxidative stress biomarkers
have been evaluated in different studies on haemodi-
alysis patients, but we have demonstrated that the
lesser-used PAB is a very powerful marker of oxidative
stress and it should be a biomarker of interest in the
future studies.
In our study, more than half of the patients (56.5%)
had hsCRP levels above 3mg/L, and 39.7% patients had
hsCRP levels above the cutoff for infections in our hos-
pital (5mg/L), although in the survival group the
median of hsCRP was 2.59mg/L with an interquartile
range 1.03–4.47mg/L. Univariate and multivariate logis-
tic regression of our data indicated that hsCRP is a
strong predictor of mortality (both all-cause and CVD).
Our findings are similar to many other studies con-
ducted on larger groups of HD patients [29,30].
The hsTnI median in our entire cohort was 21 ng/L
with interquartile range 8.75–39.75 ng/L. The overall
99th percentile cutoff value recommended by manufac-
turer is 26.2 ng/L. All our patients were asymptomatic
regarding the presence of ACS but 38.7% of them had
hsTnI concentration above the cutoff. The high preva-
lence of persistently elevated troponin levels in these
patients may reduce the diagnostic specificity of tropo-
nin for AMI [31,32]. It is well known that cardiac tropo-
nin levels are higher in patients on haemodialysis
compared to the general population, and the use of
high-sensitivity assays, which by definition can detect
cardiac troponins in 50–90% of healthy individuals
[33], increased even more the number of HD patients
with elevated levels of hsTnI or hsTnT. The median of
values in the survival group of our study was 12 ng/L
(interquartile range 7–26 ng/L) which is below the cut-
off, but the medians in both non-survival groups were
higher and univariate logistic regression analysis shows
that hsTnI is a very good prognostic marker for all-cause
and CVD mortality among patients on dialysis, while
multivariate analysis proved that the statement is only
for CVD mortality. Our results suggest that patients on
haemodialysis with a lack of ACS symptoms and base-
line values of hsTnI which are above the available cutoff
have an increased risk of death caused by cardiovascu-
lar diseases. Alam et al. have also suggested an associ-
ation between elevated troponin I levels and CVD
mortality [34]. Kaplan–Meier survival analysis for the
combination of cutoff values for hsCRP and hsTnI
showed that the highest risk of CVD mortality was
found in patients with hsCRP and hsTnI levels above
the cutoff. Of our 10 deceased patients, six were in that
group and none of them was in the group with hsCRP
and hsTnI levels below the cutoff.
Reduction in oxidative stress will lead to improve
renal function in CKD patients, and also it will lower
inflammation and CVD risk [12,35]. There are many
studies on treatments targeting oxidative stress in
patients with renal dysfunction. The suggested thera-
peutic interventions aiming to reduce oxidative stress in
HD patients include biocompatible membranes, the
administration of antioxidants and substances indirectly
affecting oxidative stress [36]. In terms of antioxidant
vitamins, the role of vitamin C is controversial, but
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vitamin E has been shown to improve the oxidant/anti-
oxidant imbalance in this group of patients.
Antioxidant-based dialysis membranes, such as vitamin
E-modified cellulose membranes to take one example,
have been shown to improve endothelial dysfunction
and reduce free radical production [28,37]. Omega-3
polyunsaturated fatty acids, N-acetyl cysteine, coen-
zyme Q10, mitochondrial-targeted antioxidants (mito-
chondrial-targeted derivative of endogenous Q10,
mitochondrial-targeted vitamin E) and carnitines have
promising potential for future therapeutic approach in
CKD patients, but multidrug therapy, targeting many
pathways modifying by oxidant processes, will be very
likely needed [35].
The limitation of our study is small sample size. Our
study was done in one centre in country with around
600,000 inhabitants. Larger multicentre studies are
needed for proving our data. Also we did not use any
therapeutic interventions using antioxidants and that
approach would be, in our opinion, very beneficial. The
main reason for doing so was number of patients on
HD treatment and impossibility to divide them into two
groups (therapeutic and control). In our study, we prove
enormous potential of PAB in oxidative stress–antioxi-
dative protection evaluation and mortality prediction.
Oxidative stress is still very difficult to measure and
monitor because of large number of markers, many of
them leaded to opposite study results and none of
them standardized. PAB was not studied that much and
that could be weak point of this study by some
researchers. We, on the contrary, think that this is also
the benefit of this study, because this marker has to be
examined by much more researchers for definitely prov-
ing its potential.
Conclusions
Our data suggest that patients decease after two years
were more exposed to inflammation and oxidative
stress compared to the survivors. PAB has shown signifi-
cant potential for mortality prediction in CKD patients.
Biomarkers of inflammation (hsCRP), oxidative stress
(PAB) and hsTnI have demonstrated that they are very
good predictors of all-cause and CVD mortality. The
combination of hsCRP and PAB values proved to be a
good tool for the assessment of all-cause mortality pre-
diction, while hsCRP and hsTnI assayed together might
target HD patients with a higher risk of developing CVD
complications and death.
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